Renal Cell Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Condition: Carcinoma, Renal Cell Interventions: Biological: Pembrolizumab; Drug: Belzutifan; Biological: Pembrolizumab/Quavonlimab; Drug: Lenvatinib Sponsors: Merck Sharp & Dohme LLC; Eisai Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials
